ES
MARKETS / NASDAQ / ELTX
NASDAQ · PHARMACEUTICAL PREPARATIONS

Elicio Therapeutics, Inc. ELTX

6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.58
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 6-year series below
Revenue Net income
0.0080.0160.0240.032-0.0202020232025
0.0080.0160.0240.032-0.0202020232025

Per share
USD -2.58
Diluted EPS, FY2025
EPS
0.40.81.2-2.58202020232025
0.40.81.2-2.58202020232025

The company pays no cash dividend.

Profitability
—
Return on equity, FY2025
ROE
0.250.50.751202020232025
0.250.50.751202020232025
Operating margin—
Net margin—
Return on assets-146.5%

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.02B
Shares outstanding, FY2025
0.020.02202020232025
0.020.02202020232025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 25.9M
total assets, end of FY2025
Total assetsUSD 25.9M
EquityUSD 1.6M
CashUSD 18.6M
Gross debtUSD 9.4M
Net debtUSD -9.2M
Current ratio2.38×

The company holds more cash than debt.

History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
·
·
·
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.0
−0.0
−0.1
−0.1
EPS, diluted $
−2.58
−4.25
−6.96
−89.27
−1.93
−5.43
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
·
−170157.4
·
·
·
·
Shares out B
0.02
0.01
0.01
0.00
0.03
0.02

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
18 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed